(Phenylamino)pyrimidine-1,2,3-triazole derivatives as analogs of imatinib: searching for novel compounds against chronic myeloid leukemia

The enzyme tyrosine kinase BCR-Abl-1 is the main molecular target in the treatment of chronic myeloid leukemia and can be competitively inhibited by tyrosine kinase inhibitors such as imatinib. New potential competitive inhibitors were synthesized using the (phenylamino)pyrimidine-pyridine (PAPP) gr...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Beilstein journal of organic chemistry Ročník 17; číslo 1; s. 2260 - 2269
Hlavní autoři:	Pimentel, Luiz Claudio Ferreira, Hoelz, Lucas Villas Boas, Canzian, Henayle Fernandes, Branco, Frederico Silva Castelo, de Oliveira, Andressa Paula, Campos, Vinicius Rangel, Júnior, Floriano Paes Silva, Dantas, Rafael Ferreira, Resende, Jackson Antônio Lamounier Camargos, Cunha, Anna Claudia, Boechat, Nubia, Bastos, Mônica Macedo
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Germany Beilstein-Institut zur Föerderung der Chemischen Wissenschaften 01.09.2021 Beilstein-Institut
Témata:	(phenylamino)pyrimidine-pyridine 1,2,3-triazole 1,3-dipolar cycloaddition BCR-ABL protein Binding sites Chemistry Chromosomes Chronic myeloid leukemia Confidence intervals Cytotoxicity Design Enzymes Full Research Paper Fusion protein Imatinib Kinases Leukemia Mutation Myeloid leukemia Protein-tyrosine kinase Triazoles (phenylamino)pyrimidine-pyridine chronic myeloid leukemia imatinib 1,2,3-triazole 1,3-dipolar cycloaddition
ISSN:	1860-5397, 2195-951X, 1860-5397
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!